SynCardia Companion 2 Driver System Post Approval Study Protocol With INTERMACS™-Based Data Collection (C2 PAS)
Study Purpose
The purpose of this PAS is to confirm that patients implanted with the temporary Total Artificial Heart (TAH-t) and supported with the Companion 2 Driver System have outcomes similar to those patients implanted with the TAH-t and supported with the CSS Console. The data collection mechanism for this study is the INTERMACS Registry.
Study Objectives
Primary Objective 1:
To confirm that patients implanted with the TAH-t and supported by the Companion 2 Driver System have outcomes similar to those patients implanted with the TAH-t and supported by the CSS Console.
Primary Objective 2:
To compare positive outcome rates for all TAH-t patients entered in the Intermacs Registry initially supported with the Companion 2 Driver System to positive outcome rates for all TAH-t patients initially supported by the CSS Console.
Primary Objective 3:
To review additional data (patient survival, adverse event rates and bridge to transplant rates) to support the conclusion that the use of an artificial heart is reasonable and necessary for the treatment of irreversible biventricular failure in Medicare/Medicaid patients.
Secondary Objective:
- To evaluate the incidence of adverse events (AEs). The AEs will follow the definitions in the INTERMACS Registry.
Study Hypothesis: Primary Objective 1 The primary hypothesis is that the positive outcome rate (defined as transplant , transfer to the Freedom Driver System support, or continuing on implant driver support, whichever occurs first; assessed at three and six months post-implant) for patients supported with the Companion 2 Driver System is non-inferior to the survival rate for patients supported with the Circulatory Support System (CSS) Console.
Data Collection The data will be collected as defined in the INTERMACS Protocol and the patients will be followed at one week, one month, three months and six months or until their study endpoint is reached.
Data Analysis
Primary Objective 1:
Data analysis will provide descriptive statistics on enrollment, adverse events, and outcomes for TAH-t patients who were implanted while supported with the Companion 2 Driver System compared to TAH-t patients who were implanted while supported with the CSS Console.
Primary Objective 2:
Data analysis will provide descriptive statistics on enrollment, adverse events, and outcomes for all TAH-t patients enrolled in the INTERMACS Registry.
Phase I as described above was completed; Phase II of Study design is under review by FDA with anticipated initiation in early 2021.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Očekávaný)
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dítě
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Implanted with the TAH-t
- Patient or their legal representative has signed an informed consent (ICF) form for INTERMACS Registry participation or waiver of consent has been approved at the implanting institution.
Exclusion Criteria:
- Patient or legal guardian has not signed an ICF for INTERMACS Registry participation, if required at the institution.
- Patient is incarcerated.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: Case-Control
- Časové perspektivy: Průřezový
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
CSS Console TAH-t Patients
All TAH-t patients implanted while supported with the CSS Console who were enrolled in the INTERMACS Registry and implanted with the TAH-t on or after June 20, 2012.
|
Comparison of two pneumatic drivers supporting the SynCardia TAH-t.
Ostatní jména:
|
|
C2 Driver System TAH-t Patients
200 TAH-t patients implanted while supported by the Companion 2 (C2) Driver System who were enrolled in the INTERMACS Registry and implanted with the TAH-t on or after June 20, 2012.
|
Comparison of two pneumatic drivers supporting the SynCardia TAH-t
Ostatní jména:
|
|
All TAH-t Patient Records
All records for TAH-t patients enrolled in the INTERMACS Registry will be reviewed to support Objective 2 of the protocol.
|
Comparison of two pneumatic drivers supporting the SynCardia TAH-t.
Ostatní jména:
Comparison of two pneumatic drivers supporting the SynCardia TAH-t
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Positive outcome rates at three months and six months Post TAH-t Implant (Concurrent Cohort)
Časové okno: Three and Six Months Post-TAH-t Implant
|
The positive outcome rates, defined as transplant, transfer to the Freedom Driver System, or continuing on implant driver support (whichever occurs first) for patients implanted on or after June 20, 2012 and supported with the Companion 2 Driver System will be compared to the positive outcome rates at three and six months for patients implanted on or after June 20, 2012 and supported with the Circulatory Support System (CSS) Console. The analysis will include a lower one-sided 95% confidence bound on the observed survival rate for patients supported with the Companion 2 Driver system which will be compared to the CSS Console survival rate to evaluate non-inferiority. |
Three and Six Months Post-TAH-t Implant
|
|
Positive outcome rates at three months and six months Post TAH-t Implant (Cumulative Cohort)
Časové okno: Three and Six Months Post-TAH-t Implant
|
The positive outcome rates, defined as transplant, transfer to the Freedom Driver System, or continuing on implant driver support (whichever occurs first) for patients supported with the Companion 2 Driver System will be compared to the positive outcome rates at three and six months for patients supported with the Circulatory Support System (CSS) Console. The analysis will include a lower one-sided 95% confidence bound on the observed survival rate for patients supported with the Companion 2 Driver system which will be compared to the CSS Console survival rate to evaluate non-inferiority. |
Three and Six Months Post-TAH-t Implant
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Review of all TAH-t patient records in the INTERMACS Registry to confirm acceptability of treatment for bi-ventricular failure.
Časové okno: Three and Six Months Post-TAH-t Implant
|
To review additional data (patient survival, adverse event rates and bridge to transplant rates) to support the conclusion that the use of an artificial heart is reasonable and necessary for the treatment of irreversible biventricular failure as ordered by the CMS National Coverage Decisions which requires enrollment of Medicare patients in approved studies for evidence development.
|
Three and Six Months Post-TAH-t Implant
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Comparison of Adverse Event Rates
Časové okno: Three and Six Months Post-TAH-t Implant or Study Endpoint, whichever occurs first.
|
To evaluate the incidence of adverse events (AEs).
The AEs will follow the definitions in the INTERMACS Registry.
|
Three and Six Months Post-TAH-t Implant or Study Endpoint, whichever occurs first.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Francisco Arabia, MD, Banner University Medical Center
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- RA-409
- Data Collection via INTERMACS (Identifikátor registru: INTERMACS Registry)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Bi-ventricular Failure
-
RWTH Aachen UniversityNeznámýBI-RADS 4 | BI-RADS 5 | BI-RADS 6 | Vysoké riziko rakoviny prsu, které indikuje Mamma-MRI
-
Meir Medical CenterNeznámýBi-trimaleolární zlomenina kotníkuIzrael
-
Rigshospitalet, DenmarkDokončenoSrdeční selhání | Kvalita života | Srdeční resynchronizační terapie | Bi-ventrikulární stimulace | Sympatická aktivitaDánsko
-
M.D. Anderson Cancer CenterNáborRefrakterní akutní leukémie | Nediferencovaná leukémie | Recidivující akutní leukémie | Bi-fenotypová leukémieSpojené státy
-
Arthrex, Inc.NáborHyperpronated Noha | Rekonstrukční operace nohy | Fixace zlomenin a fúze (bunionektomie, osteotomie) nohy/kotníku | Fixace fragmentů malých kostí chodidla/kotníku | Lisfrancová artrodéza | Mono nebo bi-kortikální osteotomie v přední části nohy | První metatarzofalangeální artrodéza | Akinova osteotomie | Artrodézy nebo osteotomie středního a zadního chodidla a další podmínkySpojené státy, Německo, Jižní Afrika
Klinické studie na CSS Console TAH-t Patients
-
SynCardia Systems. LLCNáborŽivot ohrožující | Biventrikulární srdeční selhání | Nevhodné pro transplantaci srdceSpojené státy
-
SynCardia Systems. LLCUkončenoSrdeční selhání | Srdeční selhání, pravostranné | Srdeční selhání, levostrannéSpojené státy
-
SynCardia Systems. LLCSchváleno pro marketing
-
SynCardia Systems. LLCDokončenoBiventrikulární selhání